{
  "image_filename": "figure_p1_det_0_017.png",
  "image_path": "Hsiao_et_al.__2023_/extracted/figures/figure_p1_det_0_017.png",
  "image_type": "Figure",
  "page_number": 1,
  "block_id": "det_0_017",
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "supports_claim": false,
  "explanation": "Title section of an original article labeled 'Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age' with author names. The image does not mention Flublok or Fluarix and therefore does not support the claim.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Title section of an original article labeled 'Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age' with author names.",
    "evidence_found": null,
    "reasoning": "The image does not mention Flublok or Fluarix and therefore does not support the claim.",
    "confidence_notes": null
  }
}